Asset profile
HRG2010
Small molecule
Evidence outlook · lead readout
NCT06596876 · Parkinson's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06596876: The trial randomly assigned 165 participants to HRG2010 or an active carbidopa/levodopa comparator, with participants, care providers, investigators, and outcome assessors blinded. Its primary clinical endpoint was change in “Off” time at Week 21, but results have not been posted, so whether the primary endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.